×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Molnupiravir found significantly less effective in updated study

  598 Views

eMediNexus    27 November 2021

Merck & Co announced that according to the updated data from the study of its experimental COVID-19 pill, the drug was found to be significantly less effective in reducing hospitalizations and deaths as compared to what was reported earlier.

The drug led to a 30% reduction in hospitalizations and deaths, according to data obtained from 1,433 patients. In the month of October, the study had shown an efficacy of around 50%, based on data collected from 775 patients. Provisional data from the Pfizer trial for its experimental pill in 1,200 individuals had shown an 89% reduction in hospitalizations and deaths.

A panel of outside experts is scheduled to meet on Tuesday to discuss about recommending the authorization of the pill… (Reuters, November 26, 2021)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.